Researchers at the Centre for Genomic Regulation (CRG) in Barcelona and Columbia University in New York City have found a new method for growing a large quantity of life-saving blood stem cells. The scarcity of these cells is one of the greatest limitations for their use in a variety of medical procedures, from treatment of blood cancers to inherited blood disorders that require a bone marrow transplantation.
Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse. New research led by Dana-Farber Cancer Institute scientists suggests that patients whose blood or stem cell samples harbor tumor DNA are likely to relapse.
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that isatuximab, a monoclonal antibody approved for the treatment of multiple myeloma, can effectively treat relapsed refractory AL amyloidosis, findings to be announced at the 2020 Annual Meeting of the American Society of Hematology (ASH), held virtually December 5-8, 2020.
The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.
Clonal hematopoiesis (CH) is a recently identified condition in which mutations associated with blood cancers are detected in the blood of some healthy, usually older, individuals who don't have cancer. People with CH, while asymptomatic, have an elevated risk of developing blood cancers and other negative health outcomes, including heart attacks and strokes.
This study identifies the values for six biochemical biomarkers that indicate a patient may be infected with SARS-COV-2 (COVID-19). The key novelty of this study lies in the fact that it was carried out using a blood test and can provide a determination in about 60 minutes.
Publishing in The Lancet, Australian and European researchers have released updated, evidence-based guidance for managing iron deficiency, a serious worldwide health problem. Iron deficiency is a major cause of anaemia, a lack of oxygen-carrying red blood cells or haemoglobin, which is experienced by two billion people worldwide, and can have serious long-term health consequences. Implementing the best practice diagnosing and managing iron deficiency would lead to significant long-term health benefits.
A new clinical trial offers the most compelling evidence to date that a donor stem cell transplant can improve survival rates for older patients with higher-risk myelodysplastic syndrome (MDS), Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.
Octapharma USA will present multiple clinical research posters focused on the efficacy and safety of fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use in the treatment of congenital and acquired bleeding disorders during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, a virtual medical congress to be held December 5 - 8, 2020.